Search results for " infections"

showing 10 items of 2592 documents

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, >120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

Prevalence of Extended Spectrum Beta Lactamase Producing Bacteria in Two Surgical Wards of a General Hospital

2019

Abstract Colonisation of gastrointestinal tract by extended spectrum beta lactamase (ESBL)-producing Gram-negative bacteria is a source for infections. The present work is a prospective study in Latvia aimed to determine the role of two surgical profile wards in transmission of ESBL-producing bacteria. Differences between hospital wards were not analysed due to low number of patients. We have also determined a correlation between the duration of hospitalisation and risk of ESBL colonisation. Tests for ESBL-producing bacteria were made twice for 136 patients — upon admission and upon discharge from the hospital. Of them, 21 (15.4%) patients already were ESBL-positive at the time of admission…

0301 basic medicineesblMultidisciplinarybiologygut microbiotabusiness.industrymedicine.medical_treatmentScience030106 microbiologyQbiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesMicrobiology03 medical and health sciences0302 clinical medicineBeta-lactamasemedicinepolycyclic compoundsbacteria030212 general & internal medicineGeneral hospitalbusinessBacteriabacterial colonisationProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.

2017

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety…

0301 basic medicineformalin inactivationviruksetvirusesDrug Evaluation PreclinicalPolysorbatesmedicine.disease_causeAntibodies ViralMice0302 clinical medicineMultiplicity of infectionImmunogenicity VaccinevaccineChlorocebus aethiops030212 general & internal medicineImmunogenicityVaccinationVaccinationInfectious Diseasescoxsackievirus B1Molecular MedicineFemaleUltracentrifugeVirus CultivationCoxsackievirus InfectionsBiologyCoxsackievirusta3111VirusMicrobiology03 medical and health sciencesFormaldehydemedicineAnimalsCVB1Vero CellscoxsackievirusGeneral VeterinaryGeneral Immunology and Microbiologyrokotteetta1182Public Health Environmental and Occupational HealthViral Vaccinesbiology.organism_classificationVirologyAntibodies NeutralizingVirus CultivationEnterovirus A HumanDisease Models Animal030104 developmental biologyVaccines Inactivatedvirus purificationEnterovirusVaccine
researchProduct

Importance of Sequence and Timing in Parasite Coinfections

2019

Coinfections by multiple parasites predominate in the wild. Interactionsbetween parasites can be antagonistic, neutral, or facilitative, and they canhave significant implications for epidemiology, disease dynamics, and evolu-tion of virulence. Coinfections commonly result from sequential exposure ofhosts to different parasites. We argue that the sequential nature of coinfectionsis important for the consequences of infection in both natural and man-madeenvironments. Coinfections accumulate during host lifespan, determining thestructure of the parasite infracommunity. Interactions within the parasite com-munity and their joint effect on the host individual potentially shape evolution ofparasi…

0301 basic medicineinfection dynamicsTime Factors030231 tropical medicineDisease epidemiology2405 ParasitologyVirulenceBiologyinfektiotHost-Parasite Interactions03 medical and health sciencessequential infection10127 Institute of Evolutionary Biology and Environmental Studies0302 clinical medicineloisetParasitic DiseasesParasite hostingAnimalsHumansParasitesepidemiologiaSequence (medicine)Transmission (medicine)Host (biology)Coinfectiondisease epidemiologymultiple infection2725 Infectious Diseasesvirulence evolutionPlantsMultiple infections030104 developmental biologyInfectious DiseasesParasitologyconcomitant infectionEvolutionary biologyta1181570 Life sciences; biology590 Animals (Zoology)Parasitology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Auswirkungen eines neuen Wassersystems auf nosokomiale Kolonisierung oder Infektion mit Pseudomonas aeruginosa

2016

Aim: We aimed to study the impact of new water systems, which were less contaminated with P. aeruginosa, on the incidence of healthcare-associated P. aeruginosa cases (colonizations or infections) in care units that moved to a different building between 2005 and 2014. Methods: Generalized Estimated Equations were used to compare the incidence of P. aeruginosa healthcare-associated cases according to the building. Results: Twenty-nine units moved during the study period and 2,759 cases occurred in these units. No difference was observed when the new building was compared with older buildings overall. Conclusion: Our results did not support our hypothesis of a positive association between wat…

0301 basic medicinelcsh:Public aspects of medicineTrinkwassersystem030106 microbiologylcsh:Rlcsh:QR1-502lcsh:Medicinelcsh:RA1-1270030501 epidemiology610 Medical sciences; Medicineinfection controllcsh:MicrobiologyArticlenosokomiale Infektionen3. Good healthInfektionskontrolle03 medical and health sciences[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseaseswater systemshealthcare-associated infectionsddc: 610[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesNosocomial infectionsPseudomonas aeruginosa0305 other medical scienceGMS Hygiene and Infection Control
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection

2020

Currently, Helicobacter pylori is the unique biological carcinogenic agent. The search for antimicrobial alternatives to antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with current applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan (“Generally Recognized as Safe” approval – European Commission December 2017) from different species of Phaeophyceae algae (Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera) against H. pylori. All the studied fucoidans showed bacteriostatic and bactericidal effects at the studied concentrations [5–100] μg ml−1 and exposure times [0–7 days…

0301 basic medicinemedicine.drug_classAntibioticsPhaeophytaMicrobiologyHelicobacter Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalAnti-Infective AgentsIn vivoPolysaccharidesGenerally recognized as safemedicineAnimalsCaenorhabditis elegansPathogenbiologyHelicobacter pyloriFucoidanGeneral MedicineHelicobacter pyloribiology.organism_classificationAntimicrobial3. Good healthDisease Models Animal030104 developmental biologychemistry030220 oncology & carcinogenesisFood Science
researchProduct

Minor environmental concentrations of antibiotics can modify bacterial virulence in co-infection with a non-targeted parasite.

2018

Leakage of medical residues into the environment can significantly impact natural communities. For example, antibiotic contamination from agriculture and aquaculture can directly influence targeted pathogens, but also other non-targeted taxa of commensals and parasites that regularly co-occur and co-infect the same host. Consequently, antibiotics could significantly alter interspecific interactions and epidemiology of the co-infecting parasite community. We studied how minor environmental concentrations of antibiotic affects the co-infection of two parasites, the bacterium Flavobacterium columnare and the fluke Diplostomum pseudospathaceum , in their fish host. We found that antibiotic in …

0301 basic medicinemedicine.drug_classAntibioticsVirulenceOxytetracyclineAquacultureTrematode InfectionsinfektiotFlavobacteriumantibioticsMicrobiologybakteerit03 medical and health sciencesFish DiseasesAntibiotic resistanceco-infectionAquacultureFlavobacteriaceae InfectionsloisetDrug Resistance BacterialmedicineWater Pollution ChemicalParasite hostingAnimalsbacteriabiologyVirulencebusiness.industryCoinfectionimumadotta1183antibiootitvirulenssiCommensalismbiology.organism_classificationAgricultural and Biological Sciences (miscellaneous)Anti-Bacterial Agents030104 developmental biology13. Climate actionympäristövaikutuksetOncorhynchus mykissFlavobacterium columnareparasiteta1181TrematodaGeneral Agricultural and Biological SciencesbusinessPathogen BiologyBacteriaBiology letters
researchProduct

The unusual structure of Ruminococcin C1 antimicrobial peptide confers clinical properties.

2020

The emergence of superbugs developing resistance to antibiotics and the resurgence of microbial infections have led scientists to start an antimicrobial arms race. In this context, we have previously identified an active RiPP, the Ruminococcin C1, naturally produced by Ruminococcus gnavus E1, a symbiont of the healthy human intestinal microbiota. This RiPP, subclassified as a sactipeptide, requires the host digestive system to become active against pathogenic Clostridia and multidrug-resistant strains. Here, we report its unique compact structure on the basis of four intramolecular thioether bridges introduced post-translationally by a specific radical-SAM sactisynthase. This structure con…

0301 basic medicinemedicine.drug_class[CHIM.THER] Chemical Sciences/Medicinal ChemistryAntibioticsgut microbiomeContext (language use)Peptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry010402 general chemistry01 natural sciencesMicrobiologyClostridia03 medical and health sciencesRuminococcus gnavusantibioticmedicineRiPPHumansIntestinal Mucosa[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitologychemistry.chemical_classificationRadical SAM enzymeClostridialesMultidisciplinarybiologyRiPPs Ruminococcin C sactipeptide gut microbiome antibiotic[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyBacterial InfectionsBiological Sciencesbiology.organism_classificationAntimicrobialIntestinal epithelium[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology0104 chemical sciences3. Good healthsactipeptideAnti-Bacterial AgentsRuminococcus gnavusRiPPs030104 developmental biology[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologychemistryRuminococcin CPeptidesBacteriaProceedings of the National Academy of Sciences of the United States of America
researchProduct